Scinai Immunotherapeutics Ltd. (SCNI)

Scinai Immunotherapeutics Income Statement

Financials in millions ILS. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	4.51	5.3	7.63	4.71	2.74
Research & Development	5.21	5.77	3.25	14.53	19.38
Other Operating Expenses	-0.01	0	-0.01	-21.31	0
Operating Expenses	9.71	11.06	10.86	-2.07	22.11
Operating Income	-9.71	-11.06	-10.86	2.07	-22.11
Interest Expense / Income	0	0	0	4.41	8.71
Other Expense / Income	-3.21	-5.27	-2.66	-1.08	-0
Pretax Income	-6.5	-5.8	-8.21	-1.26	-30.82
Net Income	-6.5	-5.8	-8.21	-1.26	-30.82
Shares Outstanding (Basic)	1,563	754	565	443	327
Shares Outstanding (Diluted)	1,563	754	565	443	327
Shares Change	107.22%	33.57%	27.37%	35.70%	24.95%
EPS (Basic)	-16.00	-40.00	-80.00	-11.29	-372.57
EPS (Diluted)	-16.00	-40.00	-80.00	-11.29	-372.57
Free Cash Flow	-10.02	-8.1	-7.57	-22.16	-23.85
Free Cash Flow Per Share	-25.65	-42.97	-53.60	-199.97	-292.01
EBITDA	-5.99	-5.23	-7.74	3.84	-21.65
Depreciation & Amortization	0.51	0.56	0.47	0.69	0.46
EBIT	-6.5	-5.8	-8.21	3.15	-22.11

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).